Effect of ginseng and ginsenosides on attention deficit hyperactivity disorder: A systematic review
- PMID: 39263306
- PMCID: PMC11385392
- DOI: 10.1016/j.jgr.2024.05.006
Effect of ginseng and ginsenosides on attention deficit hyperactivity disorder: A systematic review
Abstract
Attention deficit hyperactivity disorder (ADHD) is a rapidly increasing neurodevelopmental disorder but currently available treatments are associated with abuse risk, side effects, and incomplete symptom relief. There is growing interest in exploring complementary options, and ginseng has gained attention for its therapeutic potential. This systematic review aimed to assess current evidence on the efficacy of ginseng and its active components, ginsenosides, for ADHD. Eligible studies were identified through searches of PubMed, Embase, Cochrane Library, and Web of Science, up to June 2023. The inclusion criteria included both human and animal studies that investigated the effects of ginseng or ginsenosides on ADHD. The risk of bias was assessed according to study type. Six human studies and three animal studies met the inclusion criteria. The results suggest that ginseng and ginsenosides may have beneficial effects on ADHD symptoms, particularly inattention, through dopaminergic/norepinephrinergicmodulation and BDNF/TrkB signaling. Ginseng and ginsenosides have promising potential for ADHD treatment. Due to limitations in evidence quality, such as the risk of bias and variability in study designs, larger controlled studies are essential. Integrating ginseng into ADHD management may have valuable implications for individuals seeking well-tolerated alternatives or adjunctive therapies.
Keywords: Attention-deficit hyperactivity disorder; Dopamine; Ginseng; Ginsenoside; Systematic review.
© 2024 The Korean Society of Ginseng. Publishing services by Elsevier B.V.
Conflict of interest statement
There are no conflicts of interest to declare.
Figures




Similar articles
-
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.Cochrane Database Syst Rev. 2018 Aug 9;8(8):CD007813. doi: 10.1002/14651858.CD007813.pub3. Cochrane Database Syst Rev. 2018. PMID: 30091808 Free PMC article.
-
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.CNS Drugs. 2022 Aug;36(8):897-915. doi: 10.1007/s40263-022-00938-w. Epub 2022 Jul 27. CNS Drugs. 2022. PMID: 35896943 Free PMC article. Clinical Trial.
-
Attention-deficit/hyperactivity disorder and inflammation: natural product-derived treatments-a review of the last ten years.Inflammopharmacology. 2023 Dec;31(6):2939-2954. doi: 10.1007/s10787-023-01339-1. Epub 2023 Sep 23. Inflammopharmacology. 2023. PMID: 37740887 Review.
-
The Effect of Vitamin D Supplementation on Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.J Child Adolesc Psychopharmacol. 2019 Nov;29(9):670-687. doi: 10.1089/cap.2019.0059. Epub 2019 Aug 1. J Child Adolesc Psychopharmacol. 2019. PMID: 31368773
-
YY162 prevents ADHD-like behavioral side effects and cytotoxicity induced by Aroclor1254 via interactive signaling between antioxidant potential, BDNF/TrkB, DAT and NET.Food Chem Toxicol. 2014 Mar;65:280-92. doi: 10.1016/j.fct.2013.12.046. Epub 2014 Jan 3. Food Chem Toxicol. 2014. PMID: 24394491
References
-
- Arnold L.E., Hodgkins P., Kahle J., Madhoo M., Kewley G. Long-term outcomes of ADHD: academic achievement and performance. J Atten Disord. 2020;24(1):73–85. - PubMed
-
- Faraone S.V., Banaschewski T., Coghill D., Zheng Y., Biederman J., Bellgrove M.A., Newcorn J.H., Gignac M., Al Saud N.M., Manor I., et al. The world federation of ADHD international Consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789–818. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous